Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation plus PD-1 antibody and bevacizumab in hepatocellular carcinoma progressing after PD-1/L1 therapy
ChiCTR2400087586Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400087586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087586.